The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly ...
Drs. Pallabi Mustafi and Ruben Raychaudhuri at Fred Hutch Cancer Center recently received Young Investigator Awards from the ...
Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating ...
Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...
A newly developed therapy inspired by bacteria residing within tumors offers a different way to combat cancer by targeting ...
Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...
For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are ...
1d
First Patient Dosed in Phase 1 Trial Marks Expansion of NK Cell Engager Platform Into Solid Tumors
Issued on behalf of GT Biopharma, Inc. Key Takeaways - First patient dosed in Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager — the third TriKE® program to enter clinical ...
Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results